Benefits of statin therapy and compliance in high risk cardiovascular patients

Cardiovascular disease (CVD) remains the top cause of global mortality. There is considerable evidence that supports the mortality and morbidity benefit of statin therapy in coronary heart disease (CHD) and stroke, both in primary and secondary prevention settings. Data also exist pointing to the ad...

Full description

Saved in:
Bibliographic Details
Published in:Vascular health and risk management Vol. 6; no. default; pp. 843 - 853
Main Authors: Deedwania, Prakash, Lardizabal
Format: Journal Article
Language:English
Published: New Zealand Taylor & Francis Ltd 01.01.2010
Dove Press
Dove Medical Press
Subjects:
Cardiovascular disease
Cardiovascular Diseases - prevention & control
Cerebrovascular Disorders - prevention & control
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Coronary Disease - prevention & control
coronary heart disease
Diabetes Complications - prevention & control
Heart Failure - prevention & control
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Kidney Failure, Chronic - complications
long-term treatment compliance
Medication Adherence - statistics & numerical data
Mortality
Patient compliance
Peripheral Vascular Diseases - prevention & control
Primary Prevention - methods
Review
Risk Factors
statin therapy
Statins
Stroke - prevention & control
cardiovascular disease
coronary heart disease
long-term treatment compliance
statin therapy
ISSN:1178-2048, 1176-6344, 1178-2048
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease (CVD) remains the top cause of global mortality. There is considerable evidence that supports the mortality and morbidity benefit of statin therapy in coronary heart disease (CHD) and stroke, both in primary and secondary prevention settings. Data also exist pointing to the advantage of statin treatment in other high-risk CVD conditions, such as diabetes, CKD, CHF, and PVD. National and international clinical guidelines in the management of these CVD conditions all advocate for the utilization of statin therapy in appropriate patients. However, overall compliance to statin therapy remains suboptimal. Patient-, physician-, and economic-related factors all play a role. These factors need to be considered in devising approaches to enhance adherence to guideline-based therapies. To fully reap the benefits of statin therapy, interventions which improve long-term treatment compliance in real-world settings should be encouraged.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1178-2048
1176-6344
1178-2048
DOI:10.2147/VHRM.S9474